Active Ingredient History

NOW
  • Now
Lanreotide is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration on August 30, 2007. Lanreotide was developed in the lab of Dr. David H. Coy, School of Medicine. Dr. Coy serves as Director of the Peptide Laboratory. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin. Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3, and 4. Activity at human SSTR 2 and 5 is the primary mechanism believed responsible for GH inhibition. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions. Lanreotide inhibits the basal secretion of motilin, gastric inhibitory peptide and pancreatic polypeptide, but has no significant effect on the secretion of secretin. Lanreotide inhibits postprandial secretion of pancreatic polypeptide, gastrin and cholecystokinin (CCK). In healthy subjects, lanreotide produces a reduction and a delay in post-prandial insulin secretion, resulting in transient, mild glucose intolerance.   NCATS

  • SMILES: CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)[C@H](N)Cc5ccc6ccccc6c5
  • InChIKey: PUDHBTGHUJUUFI-SCTWWAJVSA-N
  • Mol. Mass: 1096.35
  • ALogP: Missing data
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

Australia

$846.9997 - $1410.6118

United States

$2698.4050 - $3132.6400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

188re-lanreotide | 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide | angiopeptin | bim 23014 | bim-23014 | bim 23014c | bim-23014c | dc 13-116 | dc-13-116 | dc13-116 | ipstyl | lanreotide | lanreotide acetate | lanreotide autogel | lanreotide-sr | l-threoninamide, 3-(1-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide | l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide | nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-nh2 | nal-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 | naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide | naphthyl-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 | somatulin | somatulina | somatulin-autogel | somatuline | somatuline autogel | somatuline depot | somatuline la

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue